Kehong Bi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kehong Bi has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Han Zhu
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People’s Republic of China
2 shared publications - Jianmin Yang
Department of Hematology, Institute of Hematology, Changhai Hospital, Naval Medical University, Shanghai 200433, China
2 shared publications - Ming Jiang
Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China
2 shared publications - Shunqing Wang
Department of Hematology, Guangzhou First People’s Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China
2 shared publications - Song Wang
Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
2 shared publications - Ting Niu
Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University, China
2 shared publications
Latest Publications
- Open Access
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- 28 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 4951
Open AccessA Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study
Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy. Some patients experience prolonged remission after aggressive chemotherapy, but the only current therapy with proven curative potential is allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, not all CMML patients benefit from allo-HSCT, and many experience relapse. Relapse is the leading cause of treatment failure for CMML treated with allo-HSCT, and treatment options for patients relapsing after allo-HSCT are limited. This study conducted a nationwide multicenter real-world study to identify risk factors and develop a novel prediction model for early recurrence in CMML patient posttransplantation. Clinicians can improve the survival of CMML patients with a high risk of early recurrence by intervening as early as possible. Methods: Patients ≥18 years old with CMML treated with allo-HSCT for the first time between 2005 and 2022 were included in this nationwide, multicenter, real-world study. Twenty-seven medical centers participated in this analysis, including the derivation cohort from 26 centers and the validation cohort from another center. Information collected included demographic and clinical characteristics, previous treatments and responses, and allo-HSCT treatment details. We first calculated the univariable association of each variable with 1-year relapse in the derivation cohort. Second, the variables with p values less than 0.1 in the univariate analysis were further included as candidate predictors in the multivariate analysis using a backward stepwise logistic regression model. The variables that remained in the final model based on the outcomes of the multivariate analysis in the derivation cohort were identified as independent prognostic factors. A scoring system to predict early recurrence after allo-HSCT was also established, and scores were assigned to the prognostic factors based on the regression coefficient. Results: Using multivariable logistic regression methods with stepwise variable selection, two highly significant independent prognostic factors for the early recurrence of CMML posttransplantation were identified: bone marrow blast cell count at diagnosis (p=0.026; odds ratio [OR], 1.149; 95% confidence interval [CI], 1.02-1.30), and leukocyte count pretransplantation (p=0.005; odds ratio [OR], 1.212; 95% confidence interval [CI], 1.06-1.39). A risk grading model was constructed according to the regression coefficients. Bone marrow blast cell count 0-5% is 0 point, 5%-10% is 1 point; 10-20% is 2 points, and >20% is 3 points. Leukocyte count 0-10×10 9/L is 0 point, 10-20×10 9/L is 2 points, and >20 ×10 9/L is 4 points. The points scored for each of these two factors were added to yield the overall risk score, which ranged from zero to seven. Patients were stratified into a low-risk group (0-1 point), a intermediate-risk group (2-3 points) and a high-risk group (4-7 points). The validated internal c-statistic was 0.790 (95% CI, 0.657-0.923), and the external c-statistic was 0.710 (95% CI, 0.580-0.840). The early recurrence rates of the derivation cohort in the low-risk, intermediate-risk, and high-risk groups were 5.9%, 17.9% and 31.8% (pConclusion: CMML patients who relapse after allo-HSCT have a poor prognosis. An integrated prediction model based on clinical biomarkers was developed and externally validated, and this is the first straightforward scoring model that incorporates clinical and laboratory risk factors to evaluate the early recurrence of CMML patients after receiving allo-HSCT. This model can be effectively utilized to help improve the survival and prognosis of CMML patients by accelerating the early identification of patients at a high risk of relapse and contributing to the appropriate implementation of urgent medical support. No relevant conflicts of interest to declare.
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e1182717
P1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e1182717
Open AccessP1277: IMPACT OF A NOVEL PROGNOSTIC MODEL ON ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN PATIENTS WITH CMML
- Open Access
- 6 May 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (17) , e29219
Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma
Rationale: Nodal marginal zone B-cell lymphoma (NMZL) is a relatively rare indolent lymphoma that is the least common subtype of marginal zone B-cell lymphoma. Furthermore, coexistence of lymphoma and multiple myeloma (MM) is rare. Here, we report a case of the coexistence of NMZL and MM. Patient concerns: The patient was a 66-year-old man with pain in the left rib and lower left back. Enlarged lymph nodes were palpable in the cervical and inguinal regions, the biggest of which was 4.0 × 2.0 cm in size in the left groin. Diagnosis: Pathological and immunohistochemical findings of the left inguinal lymph node revealed NMZL. The patient met the diagnostic criteria for symptomatic MM. Therefore, the patient was diagnosed with NMZL and lambda-type MM. Intervention: We adopted a bortezomib, liposomal adriamycin, and dexamethasone (PAD) chemotherapy regimen mainly for MM. Outcomes: After 3 cycles of treatment, the patient achieved complete remission of myeloma. A 50% decrease in enlarged lymph node size was observed. Lesson: To our knowledge, this is the first case report of the simultaneous occurrence of NMZL and MM. Further studies are required to explain the association between these 2 tumors and improve treatment selection.
- 6 May 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (17) , e29219
Open AccessCoexistence of nodal marginal zone B-cell lymphoma and multiple myeloma
Rationale: Nodal marginal zone B-cell lymphoma (NMZL) is a relatively rare indolent lymphoma that is the least common subtype of marginal zone B-cell lymphoma. Furthermore, coexistence of lymphoma and multiple myeloma (MM) is rare. Here, we report a case of the coexistence of NMZL and MM. Patient concerns: The patient was a 66-year-old man with pain in the left rib and lower left back. Enlarged lymph nodes were palpable in the cervical and inguinal regions, the biggest of which was 4.0 × 2.0 cm in size in the left groin. Diagnosis: Pathological and immunohistochemical findings of the left inguinal lymph node revealed NMZL. The patient met the diagnostic criteria for symptomatic MM. Therefore, the patient was diagnosed with NMZL and lambda-type MM. Intervention: We adopted a bortezomib, liposomal adriamycin, and dexamethasone (PAD) chemotherapy regimen mainly for MM. Outcomes: After 3 cycles of treatment, the patient achieved complete remission of myeloma. A 50% decrease in enlarged lymph node size was observed. Lesson: To our knowledge, this is the first case report of the simultaneous occurrence of NMZL and MM. Further studies are required to explain the association between these 2 tumors and improve treatment selection.
- Open Access
- 1 May 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3629-3637
CircRNA circ_POLA2 is Upregulated in Acute Myeloid Leukemia (AML) and Promotes Cell Proliferation by Suppressing the Production of Mature miR-34a
Purpose: CircRNA circ_POLA2 has been reported as an oncogene in lung cancer, while its role in other malignancies is unknown. This study aimed to explore the role of circ_POLA2 in acute myeloid leukemia (AML). Methods: The expression levels of circ_POLA2, mature miR-34a and miR-34a precursor in bone marrow mononuclear cells (BMMNCs) from AML patients (n = 50) and healthy controls (n = 50) were determined by RT-qPCR. Correlations among them were analyzed by Pearson’s correlation coefficient. Overexpression of circ_POLA2 was achieved in AML cell lines, followed by the measurement of the expression levels of mature miR-34a and miR-34a precursor. The role of circ_POLA2 and miR-34a in regulating AML cell proliferation was assessed by CCK-8 assay. Results: Circ_POLA2 was upregulated in AML and inversely correlated with mature miR-34a, but not miR-34a precursor. In AML cells, overexpression of circ_POLA2 decreased the expression levels of mature miR-34a, but not miR-34a precursor. Cell proliferation analysis showed that the overexpression of miR-34a attenuated the effects of overexpression of circ_POLA2 on cell proliferation. Conclusion: Circ_POLA2 is upregulated in AML and promotes cell proliferation by suppressing the production of mature miR-34a.
- 1 May 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 3629-3637
Open AccessCircRNA circ_POLA2 is Upregulated in Acute Myeloid Leukemia (AML) and Promotes Cell Proliferation by Suppressing the Production of Mature miR-34a
Purpose: CircRNA circ_POLA2 has been reported as an oncogene in lung cancer, while its role in other malignancies is unknown. This study aimed to explore the role of circ_POLA2 in acute myeloid leukemia (AML). Methods: The expression levels of circ_POLA2, mature miR-34a and miR-34a precursor in bone marrow mononuclear cells (BMMNCs) from AML patients (n = 50) and healthy controls (n = 50) were determined by RT-qPCR. Correlations among them were analyzed by Pearson’s correlation coefficient. Overexpression of circ_POLA2 was achieved in AML cell lines, followed by the measurement of the expression levels of mature miR-34a and miR-34a precursor. The role of circ_POLA2 and miR-34a in regulating AML cell proliferation was assessed by CCK-8 assay. Results: Circ_POLA2 was upregulated in AML and inversely correlated with mature miR-34a, but not miR-34a precursor. In AML cells, overexpression of circ_POLA2 decreased the expression levels of mature miR-34a, but not miR-34a precursor. Cell proliferation analysis showed that the overexpression of miR-34a attenuated the effects of overexpression of circ_POLA2 on cell proliferation. Conclusion: Circ_POLA2 is upregulated in AML and promotes cell proliferation by suppressing the production of mature miR-34a.